The lawsuits allege that patients who took one of four incretin-mimetic medications for diabetes - Januvia, Janumet, Victoza or Byetta - developed pancreatic cancer. Fifty-three lawsuits have been filed in seven judicial districts, including the Southern District of California, the District of Arizona, and the District of Colorado, although the panel noted that it had been made aware of 44 additional pending actions in various districts.
In ordering the lawsuits be consolidated in the Southern District of California, the panel noted that “The majority of the pending actions, including the first-filed action, have been filed in or removed to this district.” Furthermore, all respondents - including all plaintiffs and defendants - supported consolidation in that district.
READ MORE VICTOZA CANCER LEGAL NEWS
Finally, they noted that the defendants all supported centralization of the lawsuits.
The title of the lawsuit has also been changed, from In re: Incretin Mimetics Products Liability Litigation to In re: Incretin-Based Therapies Products Liability Litigation. The case number is MDL 2452, in the Southern District of California.
Although the panel confirmed consolidation of the lawsuits, this is not a judgment on the merits of the lawsuits. Consolidation only means that the lawsuits have similar questions of fact involved, but those questions of fact have not been argued in court.